Post PCI FFR Reduces MACE

Original Title: Utilizing Post-Intervention Fractional Flow Reserve to Optimize Acute Results and the Relationship to Long-Term Outcomes

Reference: Shiv K. Agarwal, et al. JACC Cardiovascular Intervention 2016;9:1022-31

 

Courtesy of Dr. Carlos Fava.

 

FFR post PCIFractional flow reserve has shown benefits and it is considered the gold standard to assess intermediate lesions (Class IA), but its use post PCI has not been evaluated yet.

574 patients with 664 lesions were analyzed; 45% had a history of diabetes, 48% multivessel disease and 45% diffuse disease.

Previous obstruction degree by quantitative angiography was 73±15%, 96% with FFR ≤0.80 and 73% FFR ≤0.75, regardless adenosine administration technique.

After PCI with angiographically satisfactory results, 21% (143 lesions) presented a suboptimal FFR ≤0.80 (0.75±0.05). After a second intervention to this group (post balloon dilation, subsequent stent implantation, or IVUS or OCT lesion assessment) FFR increased to 0.87±0.06 (p<0.0001). 9% continued with suboptimal FFR.

This was associated to longer procedural and fluoroscopy time, but not with more contrast.

Follow up was at 31 months with 19% of patients presenting some event (62 death by any cause, 12 MI, and 60 revascularizations).

MACE predictors were ACS, diffuse lesions and ≤0.86 final FFR.

In ROC curve analyzis, final FFR cutoff value predictor of MACE was ≤0.86 (23% vs. 17% p=0.02), for death ≤0.87 (13.5% vs. 9% p=0.03) and TVR ≤0.85 (12% vs. 8% p=0.03).

Conclusion

Post PCI FFR reclassifies 20% of PCI with satisfactory results, requiring more intervention to achieve complete functional revascularization at the time of index procedure. Post PCI FFR is an independent predictor of long term evolution.

Editorial Comment

This analyzis shows the concept of PCI “Functional Optimization”, because 20% of patients present ischemia after a satisfactory angiography.

Ideally, we should identify the groups that could benefit from this strategy in order not to unnecessarily prolong procedures and to save costs.

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or any ideas here below.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....